Pharmaceutics (Nov 2021)

Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance

  • Francisca Villanueva-Flores,
  • Andrés Zárate-Romero,
  • Alfredo G. Torres,
  • Alejandro Huerta-Saquero

DOI
https://doi.org/10.3390/pharmaceutics13111965
Journal volume & issue
Vol. 13, no. 11
p. 1965

Abstract

Read online

Asparaginase (ASNase) is a widely applied chemotherapeutic drug that is used to treat Acute Lymphoblastic Leukemia (ALL); however, immune responses and silent inactivation of the drug often limit its bioavailability. Many strategies have been proposed to overcome these drawbacks, including the development of improved formulations (biobetters), but only two of them are currently on the market. Nano- and micro-encapsulation are some of the most promising and novel approaches to enhance in vivo performance of ASNase, preventing the direct contact of the enzyme with the environment, protecting it from protease degradation, increasing the enzymes catalytic half-life, and in some cases, reducing immunogenicity. This review summarizes the strategies, particularly for ASNase nano- and micro-encapsulation, and their main findings, constraints, and current gaps in the state-of-the-art knowledge. The pros and cons of the use of different nanocarriers are discussed with the idea to ultimately provide safer and more effective treatments for patients with ALL.

Keywords